The Safety and Effectiveness of mRNA Vaccines in Large-scale Vaccination: A Systematic Review Based on COVID-19 and Flu Vaccines
Main Article Content
Keywords
mRNA vaccines, COVID-19, flu vaccines, vaccine safety, vaccine effectiveness
Abstract
The COVID -19 pandemic has driven the large -scale deployment of mRNA vaccines. Despite the positive outcomes observed in initial clinical trials, in-depth, comprehensive assessments of the safety and efficacy of these vaccines across different populations r emain necessary following mass vaccination. This systematic review focuses on mRNA vaccines against COVID -19 and influenza, evaluating vaccine safety by analyzing post-vaccination adverse events and assessing efficacy by examining immunogenicity dynamics and protective effects against clinical endpoints. The findings indicate that these vaccines have high initial efficacy but wane over time, necessitating booster doses. The overall safety profile is favorable, with injection site reactions and systemic symptoms as the most common adverse reactions, and the incidence of rare adverse events shows age- and gender -related disparities. This study provides a reference for public health decision -making and vaccine development.
References
- [1] Ioannidis, J. P., Pezzullo, A. M., Cristiano, A., & Boccia, S. (2025, July). Global estimates of lives and life-years saved by COVID-19 vaccination during 2020-2024. In JAMA Health Forum (Vol. 6, No. 7, pp. e252223-e252223). American Medical Association.
- [2] Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165 -175. doi:10.1016/j.immuni.2005.06.008
- [3] Liu R, Patterson L, Yeasmin M, Kim KH, Park BR, Bhatnagar N, Raha JR, Grovenstein P, Pal SS, Le CTT, Shin CH, Du L, Kumar M, Kang SM. Low -dose multivalent COVID-19 mRNA vaccines enhance broadly cross -reactive antibodies and protective immune responses of c o-administered protein -based vaccines. Virology. 2026;110884. doi:10.1016/j.virol.2026.110884
- [4] Oyedele T, Park R, Morales K, Jain M, Sher L, Vutikullird A, Isaacs A, Jepson B, Shoemaker K, Stanley AM, Lee J, Handelsman C, Berman SC, Chang LJ. A novel SARS -CoV-2 mRNA virus -like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial. Vaccine. 2026;76:128304. doi:10.1016/j.vaccine.2026.128304
- [5] Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261-279. doi:10.1038/nrd.2017.243
- [6] Ptacek J, Devgan G, Michaud G, et al. Global analysis of protein phosphorylation in yeast. Nature. 2005;438:679-684. doi:10.1038/nature04187
- [7] Diaz GA, Parsons GT, Gering SK, et al. Myocarditis and pericarditis after vaccination for COVID -19. JAMA. 2021;326(12). doi:10.1001/jama.2021.13443
- [8] Levine-Tiefenbrun M, Yelin I, Alapi H, Katz R, Herzel E, Kuint J, Chodick G, Gazit S, Patalon T, Kishony R. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021;27:2108-2110. doi:10.1038/s41591-021-01543-2
- [9] Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., et al. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS -CoV-2 infections and COVID -19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet, 397(10287), 1819-1829.
- [10] Barda, Noam, et al. “Safety of the BNT162b2 mRNA Covid -19 Vaccine in a Nationwide Setting.” New England Journal of Medicine, vol. 385, no. 12, 25 Aug. 2021, pp. 1078–90, doi:10.1056/NEJMoa2110475.
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.